Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week Low at $25.74

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares reached a new 52-week low during trading on Monday . The company traded as low as $25.74 and last traded at $25.76, with a volume of 63285 shares changing hands. The stock had previously closed at $26.25.

Analysts Set New Price Targets

PCRX has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Thursday, February 8th. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Monday, March 4th. JPMorgan Chase & Co. initiated coverage on Pacira BioSciences in a report on Thursday, March 7th. They set an “overweight” rating and a $45.00 target price on the stock. TheStreet upgraded Pacira BioSciences from a “d+” rating to a “c” rating in a report on Thursday, February 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 9th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $49.50.

Pacira BioSciences Price Performance

The firm has a fifty day moving average price of $28.91 and a two-hundred day moving average price of $29.73. The stock has a market capitalization of $1.25 billion, a P/E ratio of 33.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, hitting analysts’ consensus estimates of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The company had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million. As a group, analysts expect that Pacira BioSciences, Inc. will post 2.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now owns 22,127 shares in the company, valued at approximately $677,086.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the completion of the sale, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gary W. Pace sold 90,000 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the transaction, the director now owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of Pacira BioSciences by 9.4% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company’s stock valued at $157,000 after purchasing an additional 438 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Pacira BioSciences by 96.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock worth $36,000 after acquiring an additional 583 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC grew its position in Pacira BioSciences by 5.6% in the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 11,185 shares of the company’s stock worth $343,000 after acquiring an additional 590 shares in the last quarter. Illinois Municipal Retirement Fund grew its position in Pacira BioSciences by 2.2% in the fourth quarter. Illinois Municipal Retirement Fund now owns 26,964 shares of the company’s stock worth $910,000 after acquiring an additional 591 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in Pacira BioSciences by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 13,064 shares of the company’s stock worth $401,000 after acquiring an additional 597 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.